Purchase this article with an account.
I. Offermann, M. Hoer, M. Tan, S. Puls, A. J. Augustin; Pegaptanib-Enhancement of Intravitreal Bevacizumab Therapy for Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4546.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the effect of intravitreal pegaptanib-enhanced bevacizumab therapy for CNV due to age-related macular degeneration (AMD).
43 eyes of 43 patients suffering from CNV due to AMD have been treated with a combination of intravitreal bevacizumab and pegaptanib. All lesion types (from 0-100% classic) were included in this case series. Mean lesion size at baseline was 3100 µm. Patients attended follow-up visits every 6 weeks, undergoing VA and intraocular pressure measurement, slit-lamp and ophthalmoscopic examination, and optical coherence tomography (OCT). Fluorescein angiography was performed every 3 months or earlier if OCT showed significant edema.
All patients have been treated by one bevacizumab injection, followed by an injection of pegaptanib. Only 68.1% of the patients with remaining CNV activity needed a retreatment with intravitreal bevacizumab. After a mean follow-up of 28 weeks (up to 44 weeks) 51.2% of the patients gained one or more lines of vision, 30.2% of the patients had stable vision, and 18,6% lost one or more lines. Mean decrease of retinal thickness was 158µm (P<0.01). No adverse events have been observed.
The pegaptanib-enhanced bevacizumab therapy for CNV due to AMD is well tolerated and has a promising functional and morphological outcome. In addition, the combination of these two intravitreal anti-VEGF drugs may reduce the numbers of re-treatments required.
This PDF is available to Subscribers Only